Renewal of of the proprietary products BONVIVA 150 mg/1 month tablet (box of 1 and 3) and BONVIVA 3 mg/3 months (box of 1) on the list of medicines by National Health Insurance the renewal of of BONDRONAT solution for injection and re-assessment of the actual benefit of the proprietary product BONVIVA 3 mg/3 months solution for injection, box of 4, in accordance with article R. 163-21 of the Social Security Code.
-
Clinical Benefit
Insufficient
The actual benefit of these proprietary products in comparison with the treatments that are already available is not sufficient to justify reimbursement by National Health Insurance.
Listen
